Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development

Brenda Gaydos1, Keaven M. Anderson2, Donald A. Berry3, Nancy Burnham4, Christy Chuang‐Stein5, Jennifer Dudinak6, Parvin Fardipour7, Paul Gallo8, Sam Givens6, Roger J. Lewis9, Jeff Maca8, José Pinheiro8, Yili Pritchett10, Michael Krams7
1Eli Lilly and Co., Lilly Corporate Center, Indianapolis, USA
2Merck, USA
3Anderson Cancer Center, USA
4GSK, USA
5Pfizer, USA
6Roche, Switzerland
7Wyeth, USA
8Novartis, Switzerland
9Harbor-UCLA Medical Center, USA
10Abbott, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Gallo P, Chuang-Stein C, Dragaiin V, Gaydos B, Krams M, Pinheiro J. Executive summary of the PhRMA Working Group on Adaptive Designs in Clinical Drug Development. J Biopharm Stat. 2006;16:275–283.

PhRMA Working Group on Adaptive Designs. Full white paper. Drug Inf J. 2006;40:421–484.

Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006;40:437–444.

Gaydos B, Krams M, Perevozskaya I, et al. Adaptive dose response studies. Drug Inf J. 2006; 40:451–461.

Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007;17:965–995. Available at: https://doi.org/biopharmnet.com/doc/doc12005.html.

Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs—background, operational aspects, and examples. Drug Inf J. 2006;4:463–473.

Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Stat. 1992;(A)21:2833–2853.

Sandvik L, Erikssen J, Mowinckel P, Rodland EA. A method for determining the size of internal pilot studies. Stat Med. 1996;15:1587–1590.

Chuang-Stein C, Anderson K, Gallo P, Collins S. Sample size reestimation: a review and recommendations. Drug Inf J. 2006;40:475–484.

Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J-M, Ford GA. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543–2548.

Berry DA, Müller P, Grieve AP, et al. Adaptive Bayesian designs for dose-ranging drug trials. In Gatsonis C, Carlin B, Carriquiry A, eds., Case Studies in Bayesian Statistics V:99–181. New York: Springer-Verlag; 2001.

Berry DA. Bayesian clinical trials. Nature Rev Drug Discovery. 2006;5:27–36.

Gallo P, Chuang-Stein C. What should be the role of homogeneity testing in adaptive trials? Pharm Stat. 2009;8:1–4.

Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med. 2005; 24:3697–3714.

Brannath W, König F, Bauer P. Estimation in flexible two-stage designs. Stat Med. 2005;25: 3366–3381.

Brannath W, Posch M, Bauer P. Recursive combination tests. J Am Stat Assoc. 2002;97:236–244.